What is HC Wainwright's Forecast for BioNTech Q3 Earnings?

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Research analysts at HC Wainwright reduced their Q3 2025 earnings estimates for BioNTech in a research note issued to investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.12) per share for the quarter, down from their previous forecast of ($1.10). HC Wainwright currently has a "Buy" rating and a $138.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

Several other analysts also recently issued reports on BNTX. The Goldman Sachs Group initiated coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target on the stock. Truist Financial reissued a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Citigroup reaffirmed a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Finally, Morgan Stanley cut their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $137.86.

BioNTech Stock Down 0.3%

BNTX traded down $0.30 during trading on Friday, hitting $106.42. The company had a trading volume of 208,519 shares, compared to its average volume of 940,579. The firm's 50-day moving average price is $102.79 and its 200 day moving average price is $107.05. The company has a market capitalization of $25.58 billion, a PE ratio of -31.30 and a beta of 1.29. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. BioNTech has a one year low of $76.53 and a one year high of $131.49.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Daiwa Securities Group Inc. lifted its stake in BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after purchasing an additional 128 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after buying an additional 150 shares during the last quarter. Probity Advisors Inc. boosted its stake in shares of BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after acquiring an additional 154 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of BioNTech by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock worth $227,000 after acquiring an additional 209 shares during the last quarter. Finally, Midwest Professional Planners LTD. raised its stake in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after acquiring an additional 222 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.